Business
Oxford BioMedica (OXB): Eying up long-term value
Oxford BioMedica (OXB): Eying up long-term value.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value01-Jul-2019 / 07:15 GMT/BST\nHardman & Co: Eying up long-term value\n\nOxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector(R) platform. 2018 saw significant growth in gross income, the majority through licensing deals. A new R&D collaboration deal with Santen, coupled with the recent equity financing and debt repayment, demonstrate OXB's deal-making ability and its strategy to secure future, long-term potential. Near term, this R&D arrangement will provide modest additional profit, adding confidence to OXB's new net cash status in 2019.\n\nPlease click here for the full report:\n\nhttps://www.hardmanandco.com/research/corporate-research/eying-up-long-term-value/ \n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave+44 20 7194 7622\n [email protected]@[email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticate...